ODN 2137

Name: ODN 2137
SKU: CGON-14
Availability: InStock

For research use only. Not intended for any clinical use.

Cat. No. : CGON-14

Inquire for Price

Product Information

Cat. No.	CGON-14
Description	CpG oligodeoxynucleotides (or CpG ODNs) are synthetic oligonucleotides that contain unmethylated CpG motifs. CpG ODN can bind to and activate a Toll-like receptor 9 (TLR9) and leading to strong immunostimulatory effects. So far 3 major classes of CpG ODNs have been identified, based on their structural and biological characteristics, and are designated Type A, Type B, and Type C. Type A ODNs, which feature a central palindromic CpG-containing phosphodiester (PO) structure followed by a phosphorothioate (PS) homopolymeric G-stretch, are robust inducers of interferon-α (IFN-α) production and dendritic cell maturation. Type B ODNs, in contrast, contain a full phosphorothioate backbone with one or more CpG dinucleotides. They strongly activate B cells but stimulate weakly IFN-α secretion. Type C ODNs, combine the properties of both Type A and B, and are characterized by their complete PS backbone and palindromic CpG-containing motifs. Type C ODNs induce strong IFN-α production from pDC and B cell stimulation. ODN 2137 can be used as a control for ODN 2006.
Features	• Classification: Type B control • Product format: Lyophilized product • Sequence: 5'-tgctgcttttgtgcttttgtgctt-3' (lower case letters are phosphorothioate) • Specificity: Control for ODN 2006
Storage	Store lyophilized product at -20°C. Upon reconstitution, aliquots should be stored at -20°C and are stable for 6 months. Avoid repeated freeze-thaw cycles.

Quick Inquiry

Q & A

Customer Reviews

Customer Q&As

How does the mechanism of action of ODN 2137 differ from that of other TLR9 antagonists, and what makes it uniquely effective?

A: ODN 2137, like some other TLR9 antagonists, is a synthetic oligodeoxynucleotide. Its unique sequence and modifications allow it to bind to TLR9 with high specificity, blocking the receptor's interaction with stimulatory CpG motifs. Its effectiveness may be attributed to its enhanced binding affinity and resistance to nuclease degradation.

Are there any known off-target effects or interactions of ODN 2137 with other Toll-like receptors or intracellular signaling proteins?

A: While ODN 2137 is designed to selectively target TLR9, potential interactions with other TLRs or intracellular molecules cannot be ruled out. Rigorous specificity tests and comprehensive cellular assays are needed to fully elucidate any off-target effects.

How does ODN 2137 modulate the downstream signaling cascades and cytokine production in dendritic cells and B cells?

A: ODN 2137 acts as an antagonist, inhibiting the activation of TLR9. As a result, it suppresses downstream signaling pathways such as NF-κB activation, leading to a reduction in pro-inflammatory cytokine production in dendritic cells and B cells.

In terms of pharmacokinetics, how is the distribution and elimination profile of ODN 2137 characterized in in vivo studies?

A: The pharmacokinetics of ODN 2137 would depend on several factors, including route of administration and animal model used. Typically, detailed in vivo studies are required to ascertain its distribution, metabolism, and excretion profiles.

What is the potential of ODN 2137 in combination therapies, especially when paired with other immunomodulatory agents?

A: ODN 2137, with its ability to modulate TLR9 signaling, could synergize with other immunomodulatory agents to achieve enhanced therapeutic effects. Preliminary combination studies would be required to determine efficacy, optimal dosing, and potential synergistic effects.

Are there any documented cellular or systemic side effects when using ODN 2137 at high concentrations in prolonged treatments?

A: As with any bioactive compound, prolonged exposure or high concentrations of ODN 2137 might have potential cellular or systemic side effects. It's imperative to monitor cell viability, physiological parameters, and overall health during experimental studies to assess the compound's safety.

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Question *

Name

Country *

Email *

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Product Name *

Catalog Name *

Rating

Needs improvement

Satisfaction

General satisfaction

Very satisfaction

Product Review Title *

Summary *